← Product Code [GKZ](/submissions/HE/subpart-f%E2%80%94automated-and-semi-automated-hematology-devices/GKZ) · K061150

# SYSMEX AUTOMATED HEMATOLOGY ANALYZER, XT-SERIES (K061150)

_Sysmex America, Inc. · GKZ · Jul 6, 2006 · Hematology · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/HE/subpart-f%E2%80%94automated-and-semi-automated-hematology-devices/GKZ/K061150

## Device Facts

- **Applicant:** Sysmex America, Inc.
- **Product Code:** [GKZ](/submissions/HE/subpart-f%E2%80%94automated-and-semi-automated-hematology-devices/GKZ.md)
- **Decision Date:** Jul 6, 2006
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 864.5220
- **Device Class:** Class 2
- **Review Panel:** Hematology

## Indications for Use

The Sysmex® XT-Series Hematology Analyzer is a quantitative, automated hematology analyzer and leukocyte differential counter for in vitro diagnostic use in clinical laboratories. The XT- Series Body Fluid Application adds a quantitative, automated procedure for analyzing body fluids such as cerebrospinal fluid, serous fluid and synovial fluid to the XT- Series, providing enumeration of the WBCs and the RBCs.

## Device Story

The XT-Series Body Fluid Application is an automated software/reagent update for the Sysmex XT-Series Hematology Analyzer; it enables quantitative analysis of body fluids (CSF, serous, synovial). The device uses fluorescent flow cytometry (lateral scatter/fluorescence) for WBC counts and Direct Current (DC) detection for RBC counts. It is operated by laboratory personnel in clinical settings. The system processes samples to provide automated cell counts, which are displayed to the clinician. These outputs assist in the clinical assessment of body fluid samples, replacing or supplementing manual counting methods. The application provides standardized, reproducible cell enumeration, reducing the subjectivity and labor associated with manual microscopy.

## Clinical Evidence

Clinical performance was established by comparing the XT-Series Body Fluid Application to the predicate XE-2100 Series Body Fluid Application. Studies demonstrated excellent correlation between the two methods, confirming equivalent performance for the enumeration of WBCs and RBCs in body fluids.

## Technological Characteristics

Automated hematology analyzer utilizing flow cytometry principles. Sensing involves side scatter, forward scatter, and fluorescent intensity of nucleated cells. Reagents include Cellpack, Sulfolyser, Stromatolyser-FB, Stromatolyser-4DL, Stromatolyser-4DS, and Ret-Search II. The system is designed for clinical laboratory use.

## Regulatory Identification

An automated differential cell counter is a device used to identify one or more of the formed elements of the blood. The device may also have the capability to flag, count, or classify immature or abnormal hematopoietic cells of the blood, bone marrow, or other body fluids. These devices may combine an electronic particle counting method, optical method, or a flow cytometric method utilizing monoclonal CD (cluster designation) markers. The device includes accessory CD markers.

## Special Controls

*Classification.* Class II (special controls). The special control for this device is the FDA document entitled “Class II Special Controls Guidance Document: Premarket Notifications for Automated Differential Cell Counters for Immature or Abnormal Blood Cells; Final Guidance for Industry and FDA.”

## Predicate Devices

- Sysmex XE-Series Body Fluid Application ([K061150](/device/K061150.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number:
K061150

B. Purpose for Submission:
Added indication on the Sysmex® XT Series Automated Hematology Analyzer

C. Measurand:
White Blood Cell Count (WBC) and Red Blood Cell Count

D. Type of Test:
The XT-Series Body Fluid Application adds a quantitative, automated procedure for analyzing body fluids such as cerebrospinal fluid, serous fluid, and synovial fluid to the XT-Series, providing enumeration of the WBCs and RBCs.

E. Applicant:
Sysmex America, Inc.

F. Proprietary and Established Names:
Body Fluid Application for the XT-Series Automated Hematology Analyzer

G. Regulatory Information:
1. Regulation section:
21 CFR 864.5220, Automated differential cell counter
2. Classification:
Class II
3. Product code:
GKZ

{1}

4. Panel:
Hematology (81)

H. Intended Use:

1. Intended use(s):
The Sysmex XT-Series Hematology Analyzer is a quantitative, automated hematology analyzer and leukocyte differential counter for in vitro diagnostic use in clinical laboratories.

2. Indication(s) for use:
The XT-Series Body Fluid Application adds a quantitative, automated procedure for analyzing body fluids such as cerebrospinal fluid, serous fluid and synovial fluid to the XT-Series, providing enumeration of the WBCs and the RBCs.

3. Special conditions for use statement(s):
These matrices have been validated on the XT-Series: Cerebrospinal fluid, serous fluid (peritoneal, pleural, ascites, dialysate, pericardial, paracentesis, abdominal thoracentesis, trach aspiration, and bronchial fluid) and synovial fluid.

4. Special instrument requirements:
Sysmex Automated Hematology Analyzer, XT-Series.

I. Device Description:
The XT-Series Body Fluid Application adds a quantitative, automated procedure for analyzing body fluids such as cerebrospinal fluid, serous fluid and synovial fluid to the XT-Series, providing enumeration of the WBCs and the RBCs.

J. Substantial Equivalence Information:

1. Predicate device name(s):
Sysmex XE-2100 Series Body Fluid Application

2. Predicate 510(k) number(s):
K040073

{2}

3. Comparison with predicate:

|  Similarities  |   |   |
| --- | --- | --- |
|  Item | Device | Predicate  |
|  Intended Use | To provide a quantitative determination of blood cells in body fluids such as cerebrospinal fluid, serous fluid, and synovial fluid. | Same  |
|  Methodology | Cell count is performed on an automated hematology analyzer. | Same  |
|  Specimen Type | Body fluids such as cerebrospinal fluid, serous fluid, and synovial fluid. | same  |
|  Differences  |   |   |
| --- | --- | --- |
|  Item | Device | Predicate  |
|  Reagents | Cellpack, Sulfolyser
Stromatolyser-FB
Stromatolyser-4DL
Stromatolyser-4DS
Stromatolyser-NR
Stromatolyser-IM
Cellsheath
Ret-Search II | Cellpack Sulfolyser
Stromatolyser-FB
Stromatolyser-4DL
Stromatolyser-4DS  |
|  Accuracy | Comparison to the XE-2100 Series Body Fluid Application demonstrated excellent correlation. | Performance was established in a previous 510(k) using a manual method.  |

K. Standard/Guidance Document Referenced (if applicable):

Premarket Notifications for Automated Differential Cell Counters for Immature or Abnormal Cells; Final Guidance for Industry and FDA, December 4, 2001

L. Test Principle:

Fluorescent flow cytometry using lateral scattered light and lateral fluorescent light are used to determine the White Blood Cell count. The Direct Current (DC) detection method is used for the Red Blood Cell count.

{3}

M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

1. Within-run precision was determined by using samples that were run in the open mode ten times consecutively. Conclusion: The average CV% results for WBC samples ≥0.05 x 10³/μL and for RBC samples ≥0.01 x 10⁶/μL were acceptable.

2. Between-day precision using e-Check was monitored for the time period of the evaluation. Results were within acceptable ranges for e-Check as stated in the manufacturer’s specifications.

b. Linearity/assay reportable range:

WBC and RBC linearity were evaluated by diluting body fluid samples with instrument diluent to obtain results at low levels of detection. R squared values for WBCs ranged from 0.9974 to 1.0. R squared values for RBCs ranged from 0.9655 to 0.9990. Conclusion: The WBC and RBC parameters were linear at low levels for body fluid specimens.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

N/A

d. Detection limit:

N/A

e. Analytical specificity:

N/A

f. Assay cut-off:

N/A

{4}

# 2. Comparison studies:

a. Method comparison with predicate device:

Table 1: Accuracy of XT vs. XE White Blood Cell Counts

|  Fluid Type | N= | R | Slope | Intercept  |
| --- | --- | --- | --- | --- |
|  CSF | 47 | 1.00 | 1.0348 | -0.0022  |
|  Serous* | 150 | 1.00 | 0.9705 | 0.0625  |
|  Synovial | 33 | 1.00 | 0.9703 | 0.1571  |
|  Body Fluids combined | 228 | 1.00 | 0.9709 | 0.0644  |
|  Body Fluids ≥0.05x103/μL | 193 | 1.00 | 0.9706 | 0.0766  |

*Serous fluid included peritoneal, pleural, ascites, dialysate, pericardial, paracentesis, abdominal, thoracentesis, trach aspiration, and bronchial fluid samples.

Table 2 : Accuracy of XT vs XE Red Blood Cell Counts

|  Fluid Type | N= | R | Slope | Intercept  |
| --- | --- | --- | --- | --- |
|  Body Fluids combined | 209 | 1.00 | 1.0224 | -0.0028  |
|  Body Fluids ≥0.01x106/μL | 89 | 1.00 | 1.0205 | -0.0069  |

Table 3 : Accuracy of XT vs XE and Manual WBC and RBC Counts

|  Fluid Type | N= | R | Slope | Intercept  |
| --- | --- | --- | --- | --- |
|  WBC Body Fluids Combined | 97 | 1.00 | 0.9454 | 0.229  |
|  WBC ≥0.05x103/μL Body Fluids combined | 65 | 1.00 | 0.9441 | 0.2972  |
|  RBC Body fluids | 71 | 1.00 | 0.6632 | 0.007  |

{5}

b. Matrix comparison: All three body fluid types (CSF, Serous, Synovial) provide strong positive correlations when comparison is made between the manual counts with the automated counts.

# 3. Clinical studies:

a. Clinical Sensitivity:

N/A

b. Clinical specificity:

N/A

c. Other clinical supportive data (when a. and b. are not applicable):

Carryover: Carryover data was collected by analyzing a high sample three consecutive times then analyzing a low sample three times. Conclusion: Carryover was  $\geq 1\%$  as stated in the manufacturer specification.

Table 4: WBC and RBC Carryover (%)

|  % Carryover | WBC | RBC | Manufacturer Specification  |
| --- | --- | --- | --- |
|  CSF | 0.08 | 0.00 | ≥1%  |
|   | 0.00 | 0.00 | ≥1%  |
|   | 0.14 | 0.00 | ≥1%  |
|   | 0.00 | 0.00 | ≥1%  |
|  Serous Fluid | 0.12 | 0.00 | ≥1%  |
|   | 0.08 | 0.00 | ≥1%  |
|   | 0.16 | 0.00 | ≥1%  |
|  Synovial Fluid | 0.32 | 0.00 | ≥1%  |
|   | 0.12 | 0.00 | ≥1%  |
|   | 0.10 | 0.00 | ≥1%  |
|   | 0.27 | 0.00 | ≥1%  |
|   | -0.21 | 0.00 | ≥1%  |

# 4. Clinical cut-off:

N/A

{6}

7

5. Expected values/Reference range:

Due to the unavailability of obtaining normal body fluid samples, it is difficult for laboratories to establish expected values: therefore all laboratories will reference textbook values as their expected values as was the case with these study sites.

Table 5: Adult Expected Values for Body Fluids

|  Body Fluid Type | WBC | RBC  |
| --- | --- | --- |
|  CSF | <5 mononuclear cells/μL | NA  |
|  Peritoneal fluid | <500/mL | NA  |
|  Pleural fluid | NA (WBCs have limited value) | NA  |
|  Synovial fluid | <200/μL | NA  |

SOURCE: Kjelksberg C. and Knight J. Body Fluids: Laboratory Examination of Cerebral, Seminal, Serous, &amp; Synovial Fluids. 3rd ed. Chicago, IL: ASCP Press, 1993.

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

---

**Source:** [https://fda.innolitics.com/submissions/HE/subpart-f%E2%80%94automated-and-semi-automated-hematology-devices/GKZ/K061150](https://fda.innolitics.com/submissions/HE/subpart-f%E2%80%94automated-and-semi-automated-hematology-devices/GKZ/K061150)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com